Erlotinib/osimertinib/selpercatinibAcquired resistance, diarrhoea and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1871卷 / 1期

关键词：

D O I：

10.1007/s40278-021-01684-z

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：165 / 165

相关论文

共 50 条

[31] MirtazapineOtotoxicity and off-label use: case report
Reactions Weekly, 2024, 2037 (1) : 255 - 255
[32] PyrotinibLeukopenia and diarrhoea following off-label use: 2 case reports
Reactions Weekly, 2024, 2030 (1) : 437 - 437
[33] Cetuximab off-label useAcquired resistance: case report
Reactions Weekly, 2021, 1853 (1) : 123 - 123
[34] Multiple drugsDrug resistance, lack of efficacy and off-label use: case report
Reactions Weekly, 2023, 1960 (1) : 300 - 300
[35] Multiple drugsLack of efficacy, drug resistance and off-label use: case report
Reactions Weekly, 2021, 1851 (1) : 242 - 242
[36] Cefepime/piperacillin/tazobactamDevelopment of drug resistance and off-label use: case report
Reactions Weekly, 2023, 1943 (1) : 192 - 192
[37] Multiple drugsVancomycin resistance and thrombocytopenia following off-label use: case report
Reactions Weekly, 2023, 1958 (1) : 389 - 389
[38] Multiple drugsLack of efficacy, drug resistance and off-label use: case report
Reactions Weekly, 2023, 1961 (1) : 290 - 290
[39] Multiple drugsDrug resistance, lack of efficacy and off-label use: case report
Reactions Weekly, 2021, 1869 (1) : 240 - 240
[40] Multiple drugsLack of efficacy, drug resistance and off-label use: case report
Reactions Weekly, 2021, 1869 (1) : 247 - 247

← 1 2 3 4 5 →